Cend is a clinical-stage biotech company focused on a novel approach to enhance and more selectively deliver treatments to address a range of solid tumor cancers. Many solid tumor cancers, including pancreatic and colorectal cancers and many breast cancers are surrounded by dense fibrotic tissue. This limits the efficacy of current standard-of-care chemotherapy for these cancers. Emerging immunotherapy treatments, including checkpoint inhibitors, adoptive cell therapies such as CAR-T and NK cells, as well as nucleic acid-based therapies, such as siRNA, antisense, mRNAs and immunostimulatory oligonucleotides face challenges in penetrating solid tumors. Cend has clinical proof of concept for its tumor-targeted tissue penetrating investigational drug, CEND-1, which also holds potential to enhance immunotherapies by depleting immunosuppressive cells types.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):